EP3946236A1 - Composition topique pour le traitement des mauvaises odeurs corporelles, notamment l'halitose - Google Patents
Composition topique pour le traitement des mauvaises odeurs corporelles, notamment l'halitoseInfo
- Publication number
- EP3946236A1 EP3946236A1 EP20713026.1A EP20713026A EP3946236A1 EP 3946236 A1 EP3946236 A1 EP 3946236A1 EP 20713026 A EP20713026 A EP 20713026A EP 3946236 A1 EP3946236 A1 EP 3946236A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dianhydrohexitol
- composition according
- oral
- cyclodextrins
- topical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 230000000699 topical effect Effects 0.000 title claims abstract description 55
- 206010006326 Breath odour Diseases 0.000 title claims abstract description 19
- 208000032139 Halitosis Diseases 0.000 title claims abstract description 19
- 208000035985 Body Odor Diseases 0.000 title claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 42
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 235000019645 odor Nutrition 0.000 claims abstract description 23
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims description 23
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 15
- 229960002479 isosorbide Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 9
- 239000002781 deodorant agent Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- -1 hydroxypropyl Chemical group 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 7
- KLDXJTOLSGUMSJ-UNTFVMJOSA-N (3s,3ar,6s,6ar)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol Chemical compound O[C@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-UNTFVMJOSA-N 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 4
- 239000004875 Anti-Odour Agent Substances 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 239000000668 oral spray Substances 0.000 claims description 3
- 229940041678 oral spray Drugs 0.000 claims description 3
- 239000007935 oral tablet Substances 0.000 claims description 3
- 229940096978 oral tablet Drugs 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 3
- 229940097362 cyclodextrins Drugs 0.000 description 15
- 229940061720 alpha hydroxy acid Drugs 0.000 description 13
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 13
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 10
- 235000012209 glucono delta-lactone Nutrition 0.000 description 10
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 9
- 235000014755 Eruca sativa Nutrition 0.000 description 9
- 244000024675 Eruca sativa Species 0.000 description 9
- 150000001261 hydroxy acids Chemical class 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960003681 gluconolactone Drugs 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 229960002920 sorbitol Drugs 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000174 gluconic acid Substances 0.000 description 5
- 235000012208 gluconic acid Nutrition 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000012017 passive hemagglutination assay Methods 0.000 description 4
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 239000000182 glucono-delta-lactone Substances 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 240000002989 Euphorbia neriifolia Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008368 mint flavor Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- AAFJXZWCNVJTMK-KVTDHHQDSA-N (1S,2S)-1,2-bis[(2R)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@@H](O)[C@H](O)[C@@H]2OC2)O1 AAFJXZWCNVJTMK-KVTDHHQDSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- HFHDHCJBZVLPGP-KREQUGERSA-N 10016-20-3 Chemical compound OC[C@@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]2O[C@@H]([C@@H](O[C@@H]3O[C@@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@@H]3O[C@@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@@H]3O[C@@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H]3O[C@H]1CO HFHDHCJBZVLPGP-KREQUGERSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CEZONBVMFRWNCJ-CYGHRXIMSA-N [(3r,3ar,6s,6ar)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] dodecanoate Chemical compound O[C@@H]1CO[C@@H]2[C@@H](OC(=O)CCCCCCCCCCC)CO[C@@H]21 CEZONBVMFRWNCJ-CYGHRXIMSA-N 0.000 description 1
- BIOGOMUNGWOQHV-GMQQQROESA-N [(3s,3ar,6r,6ar)-6-octanoyloxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3-yl] octanoate Chemical compound CCCCCCCC(=O)O[C@H]1CO[C@@H]2[C@H](OC(=O)CCCCCCC)CO[C@@H]21 BIOGOMUNGWOQHV-GMQQQROESA-N 0.000 description 1
- JDRAOGVAQOVDEB-JXYJBCOESA-N [(6s)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] (e)-octadec-9-enoate Chemical compound OC1COC2[C@@H](OC(=O)CCCCCCC/C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-JXYJBCOESA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- DJDAFXBIBNKCBR-UHFFFAOYSA-N n-[2-(2-hydroxyethoxy)ethyl]acetamide Chemical compound CC(=O)NCCOCCO DJDAFXBIBNKCBR-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HXHCOXPZCUFAJI-UHFFFAOYSA-N prop-2-enoic acid;styrene Chemical class OC(=O)C=C.C=CC1=CC=CC=C1 HXHCOXPZCUFAJI-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Definitions
- the present application is in the field of cosmetics, more specifically in the field of topical care for bad odors, by the action of a topical bactericidal and / or bacteriostatic composition, and odor capture.
- the composition according to the invention can be useful for the oral sphere, but also for areas of the skin where bad odors due to microbial activity can be generated, namely the armpits, the crotch and the feet.
- the topical composition of the invention is used to treat the oral sphere, most preferably to treat halitosis.
- Application WO 2008 064948 by Henkel presents an oral washing solution comprising water, ethanol and at least one cyclodextrin.
- the oral washing solution can also comprise polyhydric alcohols such as in particular the two polyols which are xylitol and sorbitol.
- polyhydric alcohols such as in particular the two polyols which are xylitol and sorbitol.
- this washing solution buccal the presence of ethanol tends to dry out the mouth, and is aggressive to the oral mucosa.
- the aim is to find a topical composition having an "anti-odor" effect, suitable for use on the whole human body, preferably in the oral sphere, and in particular an alternative to current treatments for halitosis, which either all at the same time:
- microbiome in particular the oral microbiome, namely which promotes or maintains a balanced and healthy oral microbial flora, - and which reduces or eliminates bad odors from the first moments after its application,
- the subject of the invention is a topical, aqueous or solid composition, comprising:
- cyclodextrin chosen from alpha-cyclodextrins, beta-cyclodextrins, gamma-cyclodextrins, preferably beta-cyclodextrins,
- 1, 4-3,6-dianhydrohexitol chosen from isosorbide, isomannide, isoidide, preferably isosorbide, and / or at least one derivative of 1, 4-3,6-dianhydrohexitol .
- a second object of the invention is the non-therapeutic cosmetic use of the topical composition according to the invention as an anti-odor agent in a cosmetic or dermatological preparation.
- a third object of the invention relates to the topical composition according to the invention for its use in the treatment of bad body odor.
- the invention relates to a topical composition as described above or its use according to the invention for preventing, reducing or eliminating bad body odor.
- bad odors can be localized on the epidermis, particularly in the armpits, crotches and feet or are in the oral sphere, for example caused by halitosis.
- the non-therapeutic cosmetic use of the topical composition according to the invention is made to fight against, that is to say to prevent, reduce or eliminate, halitosis, preferably to simultaneously fight against the causes and the causes. effects of halitosis.
- the invention relates to a topical composition as described above for its use in the treatment of halitosis.
- a fourth object of the invention relates to a cosmetic or dermatological preparation comprising a topical composition as described above.
- said preparation will be in the form of an oral spray, an oral washing lotion, an oral rinsing lotion, a toothpaste, an oral tablet, a film. orodispersible.
- said preparation will be in the form of a deodorant stick, a deodorant spray, a deodorant roll-on, a deodorant mask.
- the Applicant means that the composition according to the invention has the capacity to neutralize odors, and also the capacity to prevent the formation of odors, in particular bad odors, preferably those originating from the bacterial activity of a topical microbiome, in particular the human topical microbiome, and most particularly the human oral microbiome.
- cyclodextrin denotes and includes any of the cyclodextrins known elsewhere, such as native and unsubstituted cyclodextrins containing from 6 to 12 glucose units linked by covalent bonds between the carbons 1 and 4, and in particular alpha-, beta- and gamma-cyclodextrins containing 6, 7 and 8 glucose units respectively.
- the CAS numbers for these cyclodextrins are 10016-20-3 for alpha, 7585-39-9 for beta, and 17465-86-0 for gamma.
- the “modified cyclodextrins” are cyclodextrins in which at least part of the OH hydroxyl groups has been transformed into OR groups, where R generally denotes an alkyl or carboxyalkyl group.
- the cyclodextrin derivatives include in particular cyclodextrins substituted with an alkyl group such as methylated or cyclodextrins. ethylated, but also those substituted with a hydroxyalkyl group such as hydroxypropylated and hydroxyethylated cyclodextrins, and those substituted with a carboxyalkyl group such as carboxymethylated cyclodextrins or mixtures thereof.
- the preferred cyclodextrins according to the present invention are native alpha-, beta-and gamma-cyclodextrins, that is to say unmodified.
- the cyclodextrin used in the topical composition according to the invention is a beta-cyclodextrin, preferably "native" (not chemically modified).
- the cyclodextrins preferably the modified beta-cyclodextrins will be preferred, preferably the hydroxyalkylated cyclodextrins, and all preferably hydroxyalkylated beta-cyclodextrins. Even more preferably, hydroxypropylated cyclodextrins, and most preferably hydroxypropylated beta-cyclodextrins.
- the hydroxypropylated cyclodextrins useful in the invention have a degree of substitution, denoted DS, in hydroxypropyl ranging from 0.1 to 3, preferably from 0.5 to 2, and most preferably from 1 to 1.5.
- the cyclodextrin can be in the form of a crystalline, pseudo-crystalline or amorphous powder.
- the cyclodextrin may be in a so-called "free" form, that is to say a form in which its cavity is empty, or in the known form of an inclusion complex capable of dissociating.
- the cyclodextrin is in a free form.
- the 1, 4 - 3, 6-dianhydrohexitol is chosen from isosorbide, which is 1, 4 - 3, 6-dianhydrosorbitol, isomannide, which is 1, 4 - 3.6 dianhydromannitol, l isoidide, which is 1, 4 - 3, 6-dianhydroiditol, and mixtures of at least two of these products.
- isosorbide the IUPAC name of which is (3R, 3aR, 6S, 6aR) -hexahydrofuro [3,2-b] furan-3,6-diol.
- the 1, 4: 3.6 dianhydrohexitols are products of double internal dehydration of C6 polyols (hexitols) such as sorbitol, mannitol and iditol.
- hexitols C6 polyols
- the Applicant indicates that generally the manufacture of dianhydrohexitols generates water during their synthesis; by recovering said dianhydrohexitol in this reaction medium, a 1, 4: 3.6 dianhydrohexitol is immediately available in the form of an aqueous solution of dianhydrohexitol which can be used according to the invention.
- the solutions of dianhydrohexitols can in particular be obtained according to the processes described in the aforementioned patent applications EP 1 287 000 and WO 03 / 043959. It is possible to choose to keep all or part of the water used during the preparation of dianhydrohexitol or of completely removing the water to obtain a product in solid form which will be returned to aqueous solution by simple addition of water, which constitutes another possibility for preparing an aqueous solution of dianhydrohexitol which can be used according to the invention.
- the topical composition according to the invention may comprise at least one dianhydrohexitol derivative.
- the term "derivative of 1, 4: 3.6 dianhydrohexitol” includes all the products obtained by chemical or enzymatic modification of 1, 4: 3.6 dianhydrohexitol.
- the derivative of 1, 4: 3.6 dianhydrohexitol is chosen from 1, 4: 3.6 dianhydrohexitols esterified on one or on both hydroxyl functions (we will speak of mono-ester and di-ester respectively), the 1, 4: 3.6 dianhydrohexitols etherified on one or on both hydroxyl functions (we will speak of mono-ether and di-ether respectively).
- the derivative of 1, 4: 3.6 dianhydrohexitol is chosen from monomethylisosorbide, dimethylisosorbide, isosorbide laurate, isosorbide oleate, isosorbide dicaprylate, isosorbide dicaprate , isosorbide dioleate, isosorbide dilinoleate, isosorbide dilinolenate.
- the topical composition comprises at least one alpha-hydroxy-acid or poly-hydroxy-acid or precursor of alpha-hydroxy-acid or of poly-hydroxy-acid, for example example of the lactone type, preferably a cyclic lactone such as gluconolactone, most preferably glucono-delta-lactone.
- Alpha-hydroxy acids also known by the acronym AHA, are carboxylic acids having a hydroxyl function in the "alpha" position relative to the acid function, on their main carbon chain, that is to say a hydroxyl function carried by a carbon atom adjacent to the carbon atom carrying the acid function.
- the HAAs useful for the invention are chosen from glycolic acid, malic acid, lactic acid, citric acid, tartaric acid, gluconic acid.
- said topical composition is in liquid form, and comprises an alpha-hydroxy acid chosen from glycolic acid, malic acid, lactic acid, citric acid, tartaric acid, gluconic acid, preferably is gluconic acid.
- Poly-hydroxy acids also known by the acronym PHA, are carboxylic acids having at least two hydroxyl functions carried by adjacent carbons or spaced apart by at least one carbon atom, relative to the carbon atom carrier of the carboxylic acid function.
- PHAs can be linear, branched or cyclic molecules.
- the PHAs useful for forming the anti-odor composition of the invention are selected from gluconic acid and glucuronic acid.
- precursor of alpha-hydroxy acid or poly-hydroxy acid means organic molecules comprising a chemical function capable of dissociating, for example by hydrolysis in aqueous solution, and thus of forming, by chemical equilibrium of dissociation, a molecule having a carboxylic acid function having at least one hydroxyl in position alpha, in the case of an AHA precursor, or more distant from the carboxylic acid function on the carbon chain, in the case of a PHA precursor.
- the alpha-hydroxy acid precursor is gluconolactone.
- Gluconolactone named IUPAC (3R, 4S, 5S, 6R) -3,4,5- trihydroxy-6- (hydroxymethyl) tetrahydro-2H-pyran-2-one, is the cyclic ester of gluconic acid. It is also called glucono-delta-lactone.
- said topical composition is in solid form, and comprises an alpha-hydroxy acid or poly-hydroxy acid precursor chosen from lactones, preferably from gluconolactones, and most preferably glucono-delta-lactone.
- the aqueous composition additionally comprises at least one linear polyol, chosen from glycerol, hydrogenated glucose syrups, maltitol, mannitol, sorbitol, erythritol, isomalt, lactitol, xylitol, and preferably chosen from xylitol, maltitol and sorbitol, and very preferably chosen from xylitol and maltitol.
- linear polyol chosen from glycerol, hydrogenated glucose syrups, maltitol, mannitol, sorbitol, erythritol, isomalt, lactitol, xylitol, and preferably chosen from xylitol, maltitol and sorbitol, and very preferably chosen from xylitol and maltitol.
- the topical anti-odor composition according to the invention can be in solid form, such as a powder or scales, or in fluid form, such as a paste, a gel, or a solution.
- the topical anti-odor composition is not necessarily completely anhydrous and can therefore contain water in a small amount, in particular up to approximately 5% by weight.
- a fluid form it may be a paste, a gel or an aqueous solution having a dry matter which may be between 1 and 95% by weight.
- a concentrated solution that is to say having a dry matter greater than 30% by weight, preferably greater than 50% by weight and better still greater than 70% by weight weight.
- a topical composition may be used in particular having a dry matter of between 75% and 85% by weight.
- the topical composition according to the invention has:
- a water content ranging from 0.5% to 95%, preferably from 1% to 95%, more preferably from 10% to 95%, and most preferably from 25% to 95%.
- the topical composition according to the invention has:
- a water content ranging from 0.5% to 95%, preferably from 1% to 95%, more preferably from 10% to 95%, and most preferably from 25% to 95%.
- the topical composition according to the invention has:
- a linear polyol mass content chosen from sorbitol, mannitol, xylitol, erythritol, ranging from 0.1% to 25%,
- a water content ranging from 0.5% to 95%, preferably from 1% to 95%, more preferably from 10% to 95%, and most preferably from 25% to 95%.
- Cosmetic or dermatological preparation means any cosmetic or dermatological preparation intended to be brought into contact with the skin, human or animal.
- preparations for topical use include lotions, creams , serums, gels, ointments, balms, liquid soaps or shower gels, shampoos, foams, foundations, antiperspirants and deodorants.
- the cosmetic or dermatological preparation comprising the topical composition according to the invention is in the form of an oral spray, an oral washing lotion, an oral rinsing lotion, a toothpaste, an oral tablet, an orodispersible film, a deodorant stick, a deodorant spray.
- compositions may comprise, in addition to the topical composition according to the invention, other ingredients usually used in preparations for topical use, such as for example cosmetic or dermatological active principles, and adjuvants such as preservatives, solubilizers or agents. perfumes. It can also include moisturizers such as betaine, glycerin or acetamidoethoxyethanol or other active products or products with sensory effects vis-à-vis the skin, such as starch, for example
- Cosmetic or dermatological preparations comprising the anti-odor composition according to the invention make it possible to eliminate the bad odors already present on the body before application, and to keep odorless, or weakly odorous, the part of the body treated.
- the topical composition according to the invention is used in a cosmetic preparation for oral care or hygiene, it makes it possible to deodorize instantly, and to reduce or inhibit the development of microorganisms of the oral microbiome, in particular bacteria, which reduces or prevents the formation of bad odors due to the biological activities of these bacteria.
- the topical composition according to the invention makes it possible to help keep breath fresh throughout the day, preferably for a period of more than one hour.
- the topical anti-odor composition according to the invention can inhibit the activity, and / or the development, of bacteria of the oral flora, and simultaneously capture bad odors already present in the mouth. It thus acts both on the cause of bad odors, and on bad odors themselves, without any delay between these two routes of action.
- This thus allows cosmetic preparations containing it to have an instant beneficial effect, through cyclodextrin, and a long-term effect, through 1, 4 - 3, 6-dianhydrohexitol and / or the derivative of 1, 4 - 3, 6-dianhydrohexitol.
- the topical anti-odor composition according to the invention has a rapid bactericidal and / or bacteriostatic effect, in particular antibacterial and / or antifungal, and can thus reduce or eliminate the presence of microorganisms in the mouth involved in halitosis, and thus maintaining fresh breath for a long time, typically several hours.
- the topical composition according to the invention has a moderate to strong decontaminating activity, does not induce irritation, and guarantees ease of use.
- a film-forming polymer can advantageously be added to the topical composition according to the invention, in order to develop a film on the surface of the skin or of the mucous membranes of the oral cavity, in or on which the active composition according to the invention can persist and continue to act to treat halitosis.
- Such polymers can be, for example, synthetic polymers such as polyvinylamines, polyvinylpyrrolidones, styrene acrylates, or preferably polymers of natural origin, such as, for example, cellulose or starch derivatives.
- the invention also relates to the non-therapeutic cosmetic use of a topical composition according to the invention, as an anti-odor agent in a cosmetic or dermatological preparation.
- the invention also relates to the topical composition according to the invention for its use in the treatment of bad body odor, preferably in the treatment of halitosis.
- the topical composition according to the invention or its use according to the invention makes it possible to prevent, reduce or eliminate bad body odor.
- bad odors can be localized on the epidermis, particularly in the armpits, crotches and feet, where they can be located in the oral sphere.
- the non-therapeutic cosmetic use of the topical composition makes it possible to fight against halitosis, preferably to simultaneously fight against the causes of halitosis and the effects of halitosis.
- Example 1 preparation of an anti-halitosis aqueous solution
- a topical anti-odor composition according to the invention is prepared in the form of an aqueous solution, according to the composition by mass of Table 1 below, by following the protocol below.
- phase A. is prepared.
- the xylitol powder (Beauté by Roquette® PO370, from Roquette®) and the sorbitol powder (Beauté by Roquette) are dissolved in water ® PO160, from Roquette®) in a volume of water approximately equal to half the volume of solution to be prepared, while stirring with a deflocculating paddle.
- the hydroxypropylated cyclodextrin powder (Beauté by Roquette® CD110, from Roquette®), and the aqueous isosorbide solution (Polysorb® LP, from Roquette®) are then added, successively, while waiting for complete dissolution between the two, with stirring. gentle with the deflocculator blade.
- a mint flavor is added (powdered mint flavor 023C301 from Colin Ingredients®).
- phase B can then be added, consisting of potassium sorbate (Microcare KS from Thor ⁇ ) and sodium benzoate (Microcare NB from Thor ⁇ ) in phase A, but these preservatives are not essential to the invention. They are used only to ensure microbiological stability.
- Gluconolactone is supplied by Roquette, under the trade name Beauté by Roquette® GA290.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1903283A FR3094229B1 (fr) | 2019-03-28 | 2019-03-28 | Composition topique pour le traitement des mauvaises odeurs corporelles, notamment l’halitose |
PCT/EP2020/058679 WO2020193743A1 (fr) | 2019-03-28 | 2020-03-27 | Composition topique pour le traitement des mauvaises odeurs corporelles, notamment l'halitose |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3946236A1 true EP3946236A1 (fr) | 2022-02-09 |
Family
ID=67384036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20713026.1A Pending EP3946236A1 (fr) | 2019-03-28 | 2020-03-27 | Composition topique pour le traitement des mauvaises odeurs corporelles, notamment l'halitose |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3946236A1 (fr) |
JP (1) | JP7434357B2 (fr) |
KR (1) | KR20210145759A (fr) |
CN (1) | CN113660924A (fr) |
FR (1) | FR3094229B1 (fr) |
WO (1) | WO2020193743A1 (fr) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55122709A (en) | 1979-03-13 | 1980-09-20 | Asama Kasei Kk | Stench remover from mouth |
DE4009840A1 (de) * | 1990-03-27 | 1991-10-02 | Consortium Elektrochem Ind | Cyclodextrin-polymerisate und verfahren zu deren herstellung |
US5514367A (en) * | 1994-02-28 | 1996-05-07 | Estee Lauder, Inc. | Skin tanning compositions and methods for their preparation and use |
CN1256624A (zh) * | 1996-10-24 | 2000-06-14 | 普罗克特和甘保尔公司 | 用于去除皮肤异味的组合物 |
US6656456B2 (en) * | 1998-11-23 | 2003-12-02 | The Procter & Gamble Company | Skin deodorizing compositions |
US6123932A (en) * | 1999-06-14 | 2000-09-26 | The Procter & Gamble Company | Deodorant compositions containing cyclodextrin odor controlling agents |
FR2810040B1 (fr) | 2000-06-09 | 2004-04-09 | Roquette Freres | Procede de purification d'une composition contenant au moins un produit de deshydratation interne d'un sucre hydrogene |
FR2832407B1 (fr) | 2001-11-20 | 2005-07-01 | Roquette Freres | Procede de preparation d'une composition contenant au moins un produit de deshydratation interne d'un sucre hydrogene |
JP2007169228A (ja) * | 2005-12-26 | 2007-07-05 | Lion Corp | 口臭の消臭及び/又は歯周組織の炎症抑制剤、並びに口腔用組成物 |
JP5139643B2 (ja) | 2006-04-28 | 2013-02-06 | 花王株式会社 | 液体消臭剤組成物 |
DE102006057047A1 (de) * | 2006-11-30 | 2008-06-05 | Henkel Kgaa | Stabilisierte Mundwässer und Mundwasserkonzentrate |
US20080215023A1 (en) | 2007-03-01 | 2008-09-04 | Timothy Alan Scavone | Compositions and/or articles comprising cyclodextrin complexing material |
ES2574933T3 (es) * | 2007-11-13 | 2016-06-23 | Athenion Ag | Esteroides de C-19 para usos cosméticos |
EP2574329A1 (fr) * | 2011-09-28 | 2013-04-03 | ErlaCos GmbH | Déodorant comprenant le diméthyl isosorbide |
JP2017095356A (ja) * | 2015-11-18 | 2017-06-01 | 日油株式会社 | 口腔用組成物 |
WO2017106467A1 (fr) * | 2015-12-15 | 2017-06-22 | Gontarz John A | Formulation de soins buccaux et procédé d'élimination du tartre et de la plaque des dents |
CN109289042A (zh) * | 2018-10-17 | 2019-02-01 | 李文宜 | 一种除臭液及其制备方法和应用 |
-
2019
- 2019-03-28 FR FR1903283A patent/FR3094229B1/fr active Active
-
2020
- 2020-03-27 KR KR1020217032571A patent/KR20210145759A/ko active Search and Examination
- 2020-03-27 CN CN202080021063.9A patent/CN113660924A/zh active Pending
- 2020-03-27 WO PCT/EP2020/058679 patent/WO2020193743A1/fr unknown
- 2020-03-27 JP JP2021557510A patent/JP7434357B2/ja active Active
- 2020-03-27 EP EP20713026.1A patent/EP3946236A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210145759A (ko) | 2021-12-02 |
US20220192962A1 (en) | 2022-06-23 |
WO2020193743A1 (fr) | 2020-10-01 |
FR3094229B1 (fr) | 2021-11-12 |
FR3094229A1 (fr) | 2020-10-02 |
JP7434357B2 (ja) | 2024-02-20 |
CN113660924A (zh) | 2021-11-16 |
JP2022526543A (ja) | 2022-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1001394A5 (fr) | Composition solide antitartre desodorisant la bouche et son application. | |
EP2303300B1 (fr) | Compositions visant a favoriser le developpement et la croissance d'une microflore vaginale benefique | |
FR2929509A1 (fr) | L'utilisation de glycosides d'alkyle ou de melanges de glycosides d'alkyle en tant qu'agents destines a inhiber la croissance microbienne, et compositions contenant lesdits glycosides d'alkyle. | |
JP2008303188A (ja) | カンジダバイオフィルム除去剤 | |
WO2013007961A1 (fr) | Utilisation cosmetique et/ou dermatologique de composes oligosaccharidiques pour la prevention et le traitement des vergetures | |
FR3030230A1 (fr) | Procede de coloration a partir d'orthodiphenol | |
EP3946236A1 (fr) | Composition topique pour le traitement des mauvaises odeurs corporelles, notamment l'halitose | |
CN111417438B (zh) | 双脱水己糖醇在口腔卫生中用于减少细菌菌株生长的用途 | |
JP6134943B2 (ja) | 皮膚外用剤 | |
FR2822380A1 (fr) | Utilisation d'un melange comprenant mn (ii) et/ou zn (ii) avec un hydrogenocarbonate et au moins un orthodiphenol, en tant qu'agent diminuant l'adhesion des micro-organismes | |
EP1469823B1 (fr) | Utilisation cosmetique ou dermatologique de la vitamine a ou de ses esters, en association avec une beta-cyclodextrine partiellement methylee | |
CA2747860C (fr) | Composition cosmetique comprenant un hydrolysat de gomme de caroube | |
US12029806B2 (en) | Topical composition for treating bad body odors, in particular halitosis | |
FR3069776A1 (fr) | Compositions cosmetiques pour les soins de la peau | |
FR2978040A1 (fr) | Procede de traitement de la transpiration humaine utilisant des polyphenols et un systeme catalytique d'oxydation enzymatique et/ou chimique | |
RU2777153C1 (ru) | Композиция для ухода за полостью рта для пациентов с метаболическими нарушениями | |
WO2009027330A1 (fr) | Utilisation de 2,2'-cyclolignanes pour induire, restaurer ou stimuler une pigmentation de la peau, des poils ou des cheveux | |
CA2534135A1 (fr) | Utilisation cosmetique d'un derive de biguanide en tant qu'actif anti-vieillissement de la peau | |
FR3131840A1 (fr) | Composition comprenant un polyphénol solubilisé | |
FR2917971A1 (fr) | Composition amincissante | |
KR20160026443A (ko) | 로가닉산을 포함하는 피부 주름 개선 또는 피부 탄력 증진용 조성물 | |
WO2023144487A1 (fr) | Ingredient protecteur de la peau et/ou des muqueuses contre les facteurs de virulence | |
JP2006131542A (ja) | 抗歯周病剤および該抗歯周病剤を含有する飲食物又は口腔衛生剤 | |
FR2965730A1 (fr) | Utilisation de derives de methoxyalcoxyphenyl-alkyle substitues comme conservateur, procede de conservation, composes et composition | |
FR2999085A1 (fr) | Utilisation d'un extrait de levure pour augmenter la synthese de peptides antimicrobiens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210916 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231117 |